# Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients

> **NCT04923945** · PHASE3 · COMPLETED · sponsor: **Hutchison Medipharma Limited** · enrollment: 203 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** Savolitinib

## Key facts

- **NCT ID:** NCT04923945
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-19
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-11-30
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04923945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04923945, "Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04923945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*